Discovery of novel dual adenosine $A_1/A_{2A}$ receptor antagonists using deep learning, pharmacophore modeling and molecular docking

Mukuo Wang¹, Shujing Hou¹, Yu Wei¹*, Dongmei Li¹*, Jianping Lin¹,2,3*

¹ State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin, China, 2 Biodesign Center, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin, China, 3 Platform of Pharmaceutical Intelligence, Tianjin International Joint Academy of Biomedicine, Tianjin, China

* jingningde.1988@163.com (YW); dongmeli@nankai.edu.cn (DL); jianpinglin@nankai.edu.cn (JL)

Abstract

Adenosine receptors (ARs) have been demonstrated to be potential therapeutic targets against Parkinson’s disease (PD). In the present study, we describe a multistage virtual screening approach that identifies dual adenosine $A_1$ and $A_{2A}$ receptor antagonists using deep learning, pharmacophore models, and molecular docking methods. Nineteen hits from the ChemDiv library containing 1,178,506 compounds were selected and further tested by in vitro assays (cAMP functional assay and radioligand binding assay); of these hits, two compounds (C8 and C9) with 1,2,4-triazole scaffolds possessing the most potent binding affinity and antagonistic activity for $A_1/A_{2A}$ ARs at the nanomolar level ($pK_i$ of 7.16–7.49 and $pIC_{50}$ of 6.31–6.78) were identified. Further molecular dynamics (MD) simulations suggested similarly strong binding interactions of the complexes between the $A_1/A_{2A}$ ARs and two compounds (C8 and C9). Notably, the 1,2,4-triazole derivatives (compounds C8 and C9) were identified as the most potent dual $A_1/A_{2A}$ AR antagonists in our study and could serve as a basis for further development. The effective multistage screening approach developed in this study can be utilized to identify potent ligands for other drug targets.

Author summary

Parkinson’s disease (PD) is a long-term degenerative disorder of the central nervous system. Dual adenosine $A_1/A_{2A}$ receptor antagonists provide a possible effective therapy that can simultaneously solve motor symptoms and nonmotor symptoms in the medical treatment of PD. Here, we applied a multistage virtual screening approach involving deep learning, pharmacophore models, and molecular docking methods to the ChemDiv library, which contains 1,178,506 compounds, and identified two 1,2,4-triazole derivatives as dual adenosine $A_1$ and $A_{2A}$ receptor antagonists. We used a cAMP functional assay and radioligand binding assay to evaluate the biological activity and binding affinities towards adenosine $A_1$ and $A_{2A}$ receptor of 8 selected compounds, respectively. The molecular
dynamics (MD) simulations showed similarly strong binding interactions of the complexes between the adenosine A_1/A_2A receptors and the compounds. The results showed that the multistage virtual screening approach can effectively identify potent dual adenosine A_1/A_2A receptor antagonists. The multistage screening approach offers an alternative and effective strategy for the identification of potent ligands for other drug targets.

This is a PLOS Computational Biology Methods paper.

Introduction

Parkinson’s disease (PD) is a common and complex neurodegenerative disorder that is characterized by the early prominent death of dopaminergic neurons in the substantia nigra pars compacta and the abnormal aggregation of the α-synuclein protein, called Lewy bodies and Lewy neurites [1]. Decreased dopamine in the basal ganglia can cause classical motor symptoms [2], including bradykinesia, resting tremors, and postural instability [3], and nonmotor symptoms, including constipation, depression, sleep disturbance, apathy, hallucinations and dementia [4]. L-3,4-Dihydroxyphenylalanine (L-dopa), which is the direct precursor of dopamine, is commonly used as dopamine replacement therapy in the treatment of PD motor symptoms [5]. Although L-dopa can help relieve PD motor symptoms, its chronic use may cause side effects such as motor complications (motor fluctuations and dyskinesias) [6]. In addition, dopamine receptor agonists, catechol O-methyltransferase inhibitors, monoamine oxidase B (MAOB) inhibitors, amantadine and anticholinergic drugs are available on the market for the treatment of PD [7,8]. However, these drugs are mainly used to replace the concentration and/or effect of dopamine in the brain and only solve the motor symptoms but not the nonmotor symptoms [9]. Therefore, it is necessary to develop effective therapies that simultaneously solve the motor symptoms and nonmotor symptoms in medical treatments of PD.

In recent years, adenosine receptor (AR) antagonists have attracted much attention in the development of nondopaminergic therapies for the treatment of PD. Interestingly, high-resolution structures of A_1 and A_2A adenosine receptors are available [10–20], providing an excellent opportunity for structure-based drug design (SBDD). Thus, virtual screening efforts have identified potent antagonists [21–23]. Among the four human adenosine receptors (A_1, A_2A, A_2B and A_3) [24], the A_2A receptor, which is a potential target for the treatment of PD, has been intensively studied. A_2A AR antagonists have been developed as a potential class of nondopaminergic antiparkinsonian agents that can relieve patients of symptoms of depression (nonmotor symptom of PD) [25]. The A_2A AR antagonist KW-6002 has been proven to have antidepressant activity in the forced swim test and tail suspension test in rodents [26,27]. In addition, epidemiological and experimental data indicate that adenosine A_2A receptor antagonists have neuroprotective effects [28]. Compared with A_2A AR, A_1AR is more widely distributed in the central nervous system. A_1AR is highly expressed in brain regions, including the hippocampus and prefrontal cortex. These regions are important for emotion and cognitive function. Furthermore, since A_1AR antagonists can increase the release of acetylcholine and glutamate, and improve cognitive dysfunction [29], A_1AR antagonism may improve the cognitive deficits experienced in PD as illustrated in animals studies [30].

Among the adenosine receptor antagonists, caffeine, which is a xanthine derivative, has been found to be a nonselective A_1AR and A_2AAR antagonist. Epidemiological research has
shown that a correlation exists between the intake of coffee or caffeine and a reduced risk of PD [31]. Subsequently, several dual A₁/A₂A AR antagonists were further developed and proven to not only improve dyskinesia but also enhance cognition and play a neuroprotective role through the antagonistic effect of A₂AAR [3,32,33]. Dual A₁/A₂A AR antagonists may display synergistic motor activation. A₁AR antagonism promotes presynaptic dopamine release, while A₂AAR antagonism promotes postsynaptic dopamine release [34]. In conclusion, dual A₁/A₂A AR antagonists not only treat the motor symptoms of PD and have neuroprotective effects but may also improve nonmotor symptoms [35]. In 2007, Mihara et al. discovered the dual A₁/A₂A AR antagonist 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854) (Fig 1A), which showed high affinity for human A₁ and A₂A receptors with Kᵢ values of 9.03 nM and 1.76 nM, respectively [36]. In 2008, ASP5854 was further confirmed to have activity comparable to that of existing anti-Parkinson’s disease drugs, but no further research investigating its safety was conducted [37]. In 2010, Shook et al. designed and synthesized an aryldenopyrimidine (2-amino-4-phenyl-8-(pyrrolidin-1-ylmethyl)-5H-indeno[1,2-d]pyrimidin-5-one, Fig 1B) derivative as a dual A₁/A₂A AR antagonist that has excellent activity in various animal models of PD after oral administration, but further studies revealed that it was genotoxic [3]. In 2015, Robinson et al. characterized a small set of 2-aminopyridines as dual A₁/A₂A AR antagonists. These compounds are considered useful for motor diseases, such as PD. The most potent compound found from this campaign was 4-(5-methylfuran-2-yl)-6-[3-(piperidine-1-carbonyl)phenyl]pyrimidin-2-amine (Fig 1C), which was able to bind A₁ and A₂A receptors with Kᵢ values of 9.54 nM and 6.34 nM, respectively [38,39]. Therefore, the identification of novel dual A₁/A₂A AR antagonists is of great significance for the development of novel agents for the treatment of PD [40].

Deep learning (DL), or deep neural networks, has been developed based on artificial neural networks (ANNs), which are inspired by the biological structure and function of the brain. To date, several DL frameworks, such as deep neural networks (DNNs), convolutional neural networks (CNNs), deep belief networks (DBNs), and recurrent neural networks (RNNs), have been developed. Currently, the deep learning procedure, which is the dominant component of machine learning (ML) in artificial intelligence, has emerged as a vital tool for expediting the in silico screening of potential hits [41]. Unterthiner et al. showed that the efficacy of DL in virtual drug screening was better than that of seven other screening methods using ChEMBL benchmark data [42]. Lenselink et al. demonstrated that the screening performance of DNNs outperformed that of other machine learning methods such as support vector machines, random forests, naïve Bayes and logistic regression models [43]. Bilsland et al. trained an ANN classification model to screen for senescence-inducing compounds from a library of ~2 M
lead-like compounds and identified a benzimidazolone compound with a low micromolar IC\textsubscript{50} using \textit{in vitro} assays as a potential hit for the development of selective cell cycle inhibitors [44]. Wallach et al. used CNN to design a structure-based model for the prediction of the bioactivity of small molecules for drug development and successfully predicted new active molecules for targets without known modulators [45]. Recently, Rifaioğlu et al. developed DEEPScreen, which is a novel DTI prediction system based on deep convolutional neural networks that can predict new interactions between the drug cladribine and JAK proteins as confirmed by \textit{in vitro} experiments using cancer cells [46]. Overall, deep learning plays an increasingly important role in modern drug discovery.

To date, the discovery of dual A\textsubscript{1}/A\textsubscript{2A} AR antagonists has been achieved through structural modification of specific scaffolds to obtain new compounds, while a multistage virtual screening approach combining ligand-based and structural-based methods has rarely been used. Although the rapid development of the pharmacophore [47] and molecular docking [48] methods enabled the screening of very large databases containing billions of diverse molecules, these methods are individually unable to achieve perfect effects. For example, the inaccurate scoring functions implemented in docking methods often lead to a low hit rate and a high false positive rate. In this study, a multistage virtual screening system consisting of deep learning, pharmacophore models, and molecular docking methods was used to identify novel dual A\textsubscript{1}/A\textsubscript{2A} AR antagonists from the ChemDiv database. The ChemDiv collection consists of more than 14,000 chemical families (chemotypes) and 1,250,000 diverse drug-like small molecules. Nineteen compounds were selected and tested to determine their A\textsubscript{1}AR and A\textsubscript{2A}AR functional activities; of these compounds, five compounds were found to have dual A\textsubscript{1}/A\textsubscript{2A} AR antagonistic activity through cAMP functional assays and radioligand binding assays. Among the five compounds found to have dual A\textsubscript{1}/A\textsubscript{2A} AR antagonistic activity, compounds C8 and C9, which contained a 1,2,4-triazole scaffold, showed the highest antagonistic activity, reaching nanomolar inhibition.

**Results and discussion**

**Construction and validation of the DNN and CNN models**

In this study, we used the self-developed Python script based on the algorithm from reference 50 to construct the DNN and CNN classification models of the dual A\textsubscript{1}/A\textsubscript{2A} AR antagonists using a library containing 310 bioactive dual A\textsubscript{1}/A\textsubscript{2A} antagonists (K\textsubscript{i} < 40 nM) and 405 non-bioactive antagonists (K\textsubscript{i} > 1000 nM). The models used the extended connectivity fingerprint 4 (ECFP4) [49] and neural fingerprint (NFP) [50]. Six evaluation indicators, including sensitivity (SE), specificity (SP), prediction accuracy of active molecules (Q+), prediction accuracy of inactive molecules (Q−), Matthews correlation coefficient (MCC) and area under the curve (AUC), were used to evaluate the classification ability of the models.

To assess the impact of the different batch sizes on the performance of the DNN and CNN classification models, we constructed the DNN and CNN models using batch sizes from 50 to 300 with an interval of 50. Table 1 lists the statistical evaluation results of the DNN classification models based on the ECFP4 of the test set under different batch sizes. All DNN classification models show very good SE, SP, Q+, Q−, MCC and AUC values. Among the six DNN classification models, Model_D5 based on ECFP4 has the best prediction ability, with an MCC of 0.891 and an AUC of 0.997. The optimized hyperparameters of Model_D5 which had the best performance, are as follows: batch size = 250, learning rate = 0.001, num\_epochs (number of training epochs) = 500, dropout = 0.2, L2\_regulation\_type (L2 regularization parameters) = 0.0001, three hidden layers with layer widths of 3000, 2000 and 1000, and a final fully connected layer that uses the Softmax algorithm to produce classification results.
We further analyzed the performance of the CNN models in predicting dual A₁/A₂A AR antagonists. The statistical evaluation of six CNN models based on NFP is shown in Table 2. The table shows that the batch size has a great impact on the prediction ability of the CNN classification models. Model_C6, which has a batch size of 300, shows the lowest MCC and AUC values, while Model_C4, which has a batch size of 200, shows the highest MCC and AUC values. The optimized hyperparameters of Model_C4, which has the best performance are as follows: learning rate = 0.001, num_epochs (number of training epochs) = 500, batch size = 200, L2_regulation_type (L2 regularization parameters) = 0.0001, and fingerprint_network_architecture (convolutional layers) = 5. Based on the evaluation results of the DNN and CNN classification models, Model_D5 and Model_C4, which had the best performance, were selected, and we conducted the following virtual screening of dual A₁/A₂A AR antagonists.

### Pharmacophore model generation and validation

A training set containing 14 active ingredients (S1 Table) was used to generate the dual A₁/A₂A AR antagonist pharmacophore models. Eleven hypotheses were generated, which matched 9–13 of the 14 activities. To evaluate pharmacophore hypotheses, a validation set of 42 dual antagonists of the A₁AR and A₂AAR subtypes and 913 decoy compounds was used to explore the ability of the pharmacophore hypothesis to distinguish the dual A₁/A₂A AR antagonists from the decoys. The statistical results of predicting the dual antagonists in the validation set are summarized in Table 3. The EF1% (enrichment factor in the top 1% of compounds screened) and BEDROC (α=160.9) (Boltzmann-enhanced discrimination of receiver operating characteristic) were used as “early recognition” metrics [51]. As shown in Fig 2, the AADR_4 and AAADR_1 hypotheses shared the same four pharmacophore sites including two hydrogen bond acceptors (A), one hydrogen donor (D) and one aromatic ring (R); however, the AAADR_1 hypothesis contains one additional hydrogen bond acceptor at the far end. When a minimum of four sites of the AAADR_1 model were used for screening (including the AADR_4 model), the most dual A₁/A₂A AR antagonists (39 of 42) were retrieved from the validation set, corresponding to an ROC of 0.89. Finally, the five-pharmacophore-site (AAADR_1) hypotheses, which matched 12 of the 14 active ingredients in the training set, were selected for further virtual screening.

### Table 1. Test results of the DNN classification model under different batch sizes.

| DNN Model | Batch size | SE  | SP  | Q⁺  | Q⁻  | MCC  | AUC  |
|-----------|------------|-----|-----|-----|-----|------|------|
| Model_D1  | 50         | 1   | 0.901 | 0.818 | 1  | 0.859 | 0.99 |
| Model_D2  | 100        | 0.972 | 0.901 | 0.814 | 0.986 | 0.836 | 0.989 |
| Model_D3  | 150        | 0.972 | 0.827 | 0.714 | 0.985 | 0.748 | 0.99 |
| Model_D4  | 200        | 0.889 | 0.8 | 1 | 0.843 | 0.993 |
| Model_D5  | 250        | 0.926 | 0.857 | 1 | 0.891 | 0.997 |
| Model_D6  | 300        | 1 | 0.889 | 0.8 | 1 | 0.843 | 0.978 |

https://doi.org/10.1371/journal.pcbi.1008821.t001

### Table 2. Test results of the CNN classification model under different batch sizes.

| CNN Model | Batch size | SE  | SP  | Q⁺  | Q⁻  | MCC  | AUC  |
|-----------|------------|-----|-----|-----|-----|------|------|
| Model_C1  | 50         | 0.861 | 0.877 | 0.756 | 0.934 | 0.714 | 0.941 |
| Model_C2  | 100        | 0.972 | 0.914 | 0.833 | 0.987 | 0.852 | 0.986 |
| Model_C3  | 150        | 0.944 | 0.926 | 0.85 | 0.974 | 0.847 | 0.977 |
| Model_C4  | 200        | 0.926 | 0.857 | 1 | 0.891 | 0.986 |
| Model_C5  | 250        | 0.972 | 0.926 | 0.854 | 0.987 | 0.869 | 0.985 |
| Model_C6  | 300        | 1 | 0.185 | 0.353 | 1 | 0.256 | 0.791 |

https://doi.org/10.1371/journal.pcbi.1008821.t002
Virtual screening

Our previous study showed that a multistage approach sequentially integrating machine learning classification models and pharmacophore and molecular docking methods is efficient in identifying bioactive compounds from chemical databases [52]. In this study, the performance of the hierarchical multistage virtual screening approach was evaluated through a validation set containing 433 bioactive dual A<sub>1</sub>/A<sub>2A</sub>AR antagonists (40 nM < \( K_i < 600 \) nM) and 11,605 decoys (S2 Table). Then, DNN and CNN classification models, a pharmacophore model (AAADR_1) and molecular docking were applied for the discovery of dual A<sub>1</sub>/A<sub>2A</sub>AR antagonists by performing multistage virtual screening against the ChemDiv library (1,178,506 compounds) (Fig 3). In the first stage, the DNN and CNN classification models were separately utilized to filter 1,178,506 compounds. Initially, 209,585 and 171,233 compounds passed the filter that applied the DNN and CNN classification models, respectively. In total, 58,886 compounds simultaneously predicted by the DNN and CNN classification models were retained. In the second stage, a pharmacophore model was applied to remove the compounds that were not adequate for a minimum of four sites, and 5,629 of the 58,886 compounds that matched the requirements of the AAADR_1 model were retained. In the third stage, the 5,629 compounds were subjected to molecular docking screening based on the X-ray structures of A<sub>1</sub>AR (PDB ID 5N2S) and A<sub>2A</sub>AR (PDB ID 5IU4) using Glide HTVS, SP and XP functions. After the XP molecular docking, 43 compounds that simultaneously bind A<sub>1</sub> and A<sub>2A</sub> ARs remained. Based on the assessment of chemical-protein interactions by visual inspection, 19 of the 43 compounds that matched the four pharmacophore sites (S1 Fig) were finally selected for an in vitro evaluation of their bioactivity towards A<sub>1</sub> and A<sub>2A</sub> ARs. Fig 3 shows a schematic workflow of our multistage virtual screening methods.

Biological evaluation

**Functional experiments.** Initially, the biological activity of selected compounds C1 –C19 towards A<sub>1</sub> and A<sub>2A</sub> ARs was evaluated by a cAMP functional assay. The potency of the antagonists at the A<sub>1</sub> and A<sub>2A</sub> ARs is depicted in Table 4, which shows that eight compounds (C4, C7, C8, C9, C10, C15, C17 and C19) of the 19 compounds (Fig 4) display potent antagonistic
activity against A₁AR with pIC₅₀ values ranging from 4.28 to 6.78. Regarding the eight compounds, the pIC₅₀ values at A₂AR were subsequently determined. Among all eight compounds, five compounds possessed antagonistic activity towards A₂AR with pIC₅₀ values of 4.20–6.44. The concentration-response curves of the eight compounds in the cAMP assay are depicted in S2 and S3 Figs. Notably, compounds C8 and C9 have the most potent antagonistic activity towards A₁/A₂ARs with pIC₅₀ values in the range of 6.31–6.78, while C15 has the weakest antagonistic activity towards A₁/A₂ARs with pIC₅₀ values ranging between 5.10–5.35.

**A₁/A₂AR affinity experiments.** All eight compounds with potent antagonistic activity against A₁/A₂ARs were further evaluated to determine their binding affinity against A₁ and A₂ARs by radioligand binding assays using the labeled A₁AR antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX) (Fig 5A) and A₂AR antagonist 4-[2-[[7-amino-2-(furyl) 1,2,4-triazolo[2,3-a]1,3,5-triazin-5-yl]-amino]ethyl]phenol (ZM241385) (Fig 5B). The concentration-response curves of the eight compounds in the radioligand binding assay are depicted in S4 and S5 Figs. Table 4 shows that compounds C8 and C9 also possess the highest binding affinity for A₁/A₂ARs with Kᵢ values at the nanomolar level (pKᵢ values in the range 7.16–7.49), which is consistent with the highest antagonistic potency with pIC₅₀ values in the range 6.31–6.78. Overall, these experiments confirm that compounds C8 and C9 are the most potent dual A₁/A₂AR AR antagonists among our selected compounds.
Fig 3. Schematic overview of the discovery of dual A₁/A₂A AR antagonists by performing multistage virtual screening against the ChemDiv library.

https://doi.org/10.1371/journal.pcbi.1008821.g003

Table 4. Potencies and binding activities at human A₁ and A₂A ARs of compounds C1 –C19. A₁/A₂A AR Affinity Experiments.

| Compound number | Compound ID | cAMP assays (pIC_{50}) | Binding affinities (pK_{i}) | Pharmacophore matching |
|-----------------|-------------|-------------------------|-----------------------------|------------------------|
|                 |             | A₁ | A₂A | A₁ | A₂A |                     |                         |
| C1              | 6016–3052   | < 4 | -   | -  | -   | 4                     |                         |
| C2              | C686-0670   | < 4 | -   | -  | -   | 4                     |                         |
| C3              | C884-2451   | < 4 | -   | -  | -   | 4                     |                         |
| C4              | D116-0057   | 5.51 | < 4 | 5.68 | 4.71 | 4                     |                         |
| C5              | D331-0235   | -   | -   | -  | -   | -                     | 4                       |
| C6              | D331-0346   | NAN | -   | -  | -   | -                     | 4                       |
| C7              | D481-1843   | 5.72 | < 4 | 5.98 | 5.24 | 4                     |                         |
| C8              | D481-2135   | 6.78 | 6.44 | 7.19 | 7.29 | 4                     |                         |
| C9              | D481-2142   | 6.72 | 6.31 | 7.49 | 7.16 | 4                     |                         |
| C10             | D503-0436   | 6.46 | 5.00 | 6.77 | 5.08 | 4                     |                         |
| C11             | F026-0231   | < 4 | -   | -  | -   | -                     | 4                       |
| C12             | F092-0415   | NAN | -   | -  | -   | -                     | 4                       |
| C13             | F186-0821   | < 4 | -   | -  | -   | -                     | 4                       |
| C14             | F186-0830   | < 4 | -   | -  | -   | -                     | 4                       |
| C15             | G433-0400   | 5.35 | 5.10 | 5.54 | < 4  | 4                     |                         |
| C16             | G856-9311   | < 4 | -   | -  | -   | -                     | 4                       |
| C17             | L935-0138   | 6.20 | 4.20 | 6.28 | < 4  | 4                     |                         |
| C18             | P072-0704   | < 4 | -   | -  | -   | -                     | 4                       |
| C19             | P433-0232   | 4.28 | < 4 | 4.97 | 4.93 | 4                     |                         |

https://doi.org/10.1371/journal.pcbi.1008821.t004
Novelty of the new hits

To evaluate the novelty of the identified dual $A_1/A_2A$ AR antagonists, the pairwise similarity between compounds C8 and C9 and known $A_1/A_2A$ AR antagonists, including all dual antagonists found in ChEMBL25 [53], was calculated using Morgan, ECFP4 and MACCS fingerprints in KNIME [54]. The molecular similarity between the two molecules was compared

![Chemical structures of compounds C1—C19.](https://doi.org/10.1371/journal.pcbi.1008821.g004)

**Novelty of the new hits**

To evaluate the novelty of the identified dual $A_1/A_2A$ AR antagonists, the pairwise similarity between compounds C8 and C9 and known $A_1/A_2A$ AR antagonists, including all dual antagonists found in ChEMBL25 [53], was calculated using Morgan, ECFP4 and MACCS fingerprints in KNIME [54]. The molecular similarity between the two molecules was compared

![Chemical structures of DPCPX (A) and ZM241385 (B).](https://doi.org/10.1371/journal.pcbi.1008821.g005)
using the Tanimoto coefficient (Tc), which ranges from 0 to 1. Low chemical similarity has a correlation with a Tc value close to 0, whereas high chemical similarity has a correlation with a Tc value close to 1. Regarding compounds C8 and C9, the maximum Tc values of the Morgan and ECFP4 fingerprints compared to known A₁/A₂A AR antagonists are similar and less than 0.4 (S3 Table). The maximum Tc values of MACCS and ECFP4 conform to the relationship studied by Maggiora et al.[55] (S6 Fig and S3 Table), indicating that compounds C8 and C9 are novel dual A₁/A₂A AR antagonists. Compounds C8 and C9 contain a 1,2,4-triazole core, which is a privileged scaffold for developing potent antifungal agents [56], LSD1 inhibitors [57], anticonvulsant agents [58], etc. 1,2,4-Triazole derivatives possess diverse pharmacological activities, such as antiviral, antitumor, anti-inflammatory, antibacterial, antifungal, anti-hypertensive, hypoglycemic and analgesic activities [59]. The 1,2,4-triazole scaffold was first found to have the potential to be developed as a dual A₁/A₂A AR antagonist. The associated pharmacological activity of compounds C8 and C9 acting as dual A₁/A₂A AR antagonists needs to be further studied.

Molecular modeling exploration

To explore the dual antagonistic activities of compound C8, C9 exhibited nanomolar inhibition against both A₁AR and A₂AR, and molecular docking using Glide and MD simulation studies were carried out. In our docking studies, C8 and C9 had similar binding energies against A₁AR and A₂AR (Table 5). In total, 4 complexes of C8 and C9 bound to A₁AR and A₂AR were generated, and each complex was embedded in a hydrated phospholipid bilayer including POPE lipid molecules and subjected to 100-ns MD simulation using the AMBER ff14sb force field. After 100 ns of the MD simulation we obtained a stable bilayer (S7 Fig), and the RMS prot (which is the protein backbone RMSD with respect to the minimized structure) values ranged from 2.51 to 2.96 Å with standard deviations of approximately 0.25 Å (S8 Fig). The stability of the ligand inside the binding area was assessed by measuring its RMSD (RMSD lig). Among the four docking poses used as starting structures, we obtained RMSD lig less than 2 Å (Table 5 and S9 Fig), suggesting stable binding in agreement with the experimental binding and functional data.

In addition, we calculated the binding free energy of C8 and C9 with A₁AR and A₂AR by using the MM-GBSA method based on the last 5 ns trajectory of the MD simulations (Table 5). The calculated binding free energy of the C8-A₁AR complex (ΔG_{eff} = -41.67 kcal/mol) is similar to that of the C8-A₂AR complex (ΔG_{eff} = -42.22 kcal/mol). In addition, the calculated binding energy of the C9-A₁AR complex (ΔG_{eff} = -43.55 kcal/mol) is similar to that of the C9-A₂AR complex (ΔG_{eff} = -40.70 kcal/mol). Therefore, the binding free energies show that compounds C8 and C9 have similar affinities to A₁AR and A₂AR, which is consistent with the results of the functional assay and radioligand binding assays.

**Binding modes exploration.** The 100-ns MD simulations showed that compounds C8 and C9 were stabilized with similar orientations in the binding pockets of both A₁AR and A₂AR (Fig 6). In the C8-A₁AR complex and the C9-A₁AR complex (Fig 6A and 6B), the 5-amino group and the nitrogen of the 1,2,4-triazol were hydrogen bonded to the side chain carbonyl and amino group of N254, respectively. The 1,2,4-triazol formed π-π stacking

Table 5. Glide XP scores, RMSD_{lig} and MM-GBSA binding free energies of ligands C8 and C9 against A₁AR and A₂AR.

| Compound ID | A₁AR Glide XP (kcal/mol) | RMSD_{lig} A₁ (Å) | A₁AR ΔG_{eff} (kcal/mol) | A₂AR Glide XP (kcal/mol) | RMSD_{lig} A₂ (Å) | A₂AR ΔG_{eff} (kcal/mol) |
|-------------|--------------------------|-------------------|--------------------------|--------------------------|-------------------|--------------------------|
| C8          | -11.36                   | 1.69 ± 0.23       | -41.67 ± 3.08            | -10.50                   | 0.92 ± 0.14       | -42.22 ± 2.87            |
| C9          | -11.47                   | 1.28 ± 0.24       | -43.55 ± 2.62            | -11.99                   | 1.59 ± 0.19       | -40.70 ± 2.83            |
interactions with the phenyl group of F171\textsuperscript{ECL2}. These interactions are consistent with the observations in the mutagenesis experiments that N254\textsuperscript{6.55} and F171\textsuperscript{ECL2} play important roles in antagonist binding. These interactions were maintained from the origin to the end of the 100-ns simulation (S10 Fig). Additionally, the 3-methoxyphenyl (or 3-chorophenyl) exhibited nonpolar interactions with the side chain of I274\textsuperscript{7.39}, and the 2-chorophenyl extended deeper into the other side of the pocket formed by the hydrophobic side chains of V87\textsuperscript{3.32}, L88\textsuperscript{3.33} and W247\textsuperscript{6.48}. In the C8-A\textsubscript{2A}AR complex and the C9-A\textsubscript{2A}AR complex (Fig 6C and 6D), the 5-amino group and the oxygen of the methanone formed hydrogen bonds with the side chain carbonyl and amino group of N253\textsuperscript{6.55}. Additionally, the 5-amino group formed a hydrogen bond with the carboxyl side chain of E169\textsuperscript{ECL2}. The 1,2,4-triazol interacted with the phenyl group of F168\textsuperscript{ECL2} through π-π stacking. These interactions were maintained throughout the 100-ns simulation (S11 Fig). The 2-chlorophenyl formed hydrophobic interactions with Y271\textsuperscript{7.36}, and the 3-methoxyphenyl (or 3-chorophenyl) extended deeper into the orthosteric binding area and formed hydrophobic interactions with residues V84\textsuperscript{3.32}, L85\textsuperscript{3.33}, L249\textsuperscript{6.51} and I274\textsuperscript{7.39}. Although the orientation of C8 (or C9) was different in the binding pocket of A\textsubscript{1}AR and A\textsubscript{2A}AR, the number of hydrogen bonds, π-π stacking and hydrophobic interactions were

https://doi.org/10.1371/journal.pcbi.1008821.g006
the same as those in the C8 (or C9)-A1AR complex and the C8 (or C9)-A2AAR complex, which may lead to the similar binding affinity of C8 (or C9) to A1AR and A2AAR.

To compare the binding differences between A1AR and A2AAR of nondual A1/A2A AR antagonists, we also performed MD simulations against compound C10, which has stronger binding affinity and antagonistic activity to A1AR than A2AAR. In the C10-A1AR complex, the N-propyl group and the nitrogen of the pyrazolo[1,5-a]pyrimidinformed two hydrogen bonds with the side chain carbonyl and amino group of N254.

Pyrazolo[1,5-a]pyrimidine interacted with the phenyl side chain of F171 through π-π stacking. In the C10-A2AAR complex, C10 possessed a different orientation and formed only one hydrogen bond with the amino group of N253 via the nitrogen of pyrazolo[1,5-a]pyrimidin. Pyrazolo[1,5-a]pyrimidine formed π-π stacking interactions with the phenyl side chain of F168 (Figs 7 and S12). Compared to the dual antagonists (which had similar a number of hydrogen bonds, π-π stacking and hydrophobic interactions in the two receptors), C10 had one less hydrogen bond in the C10-A2AAR complex than the C10-A1AR complex, which may be the reason for its weaker binding affinity and antagonistic activity for A2AAR.

Conclusions

In the quest for novel dual A1/A2A AR antagonists as putative agents for the treatment of Parkinson’s disease, we applied a multistage virtual screening approach combining deep learning, pharmacophore and molecular docking methods to screen the ChemDiv library (1,178,506 compounds) and tested 19 hits by in vitro assays. Initially, the cAMP functional assay identified five compounds that possessed antagonist activity towards A1/A2AAR with pIC50 values of 4.20–6.78. The radioligand binding assays confirmed that six of the eight compounds with antagonistic activity for A1AR and A2AAR (pIC50 of 4.20–6.78) also had consistent binding affinity against A1/A2A ARs (pKd of 4.71–7.49). In particular, compounds C8 and C9 showed the highest binding affinity and functional activity for A1/A2A ARs with Kd values at the nanomolar level (pKd of 7.16–7.49 and pIC50 of 6.31–6.78). Compounds C8 and C9 are novel 1,2,4-triazole derivatives acting as dual A1/A2AAR antagonists. The MD simulations of the
complexes between the A<sub>1</sub>/A<sub>2A</sub> ARs and C8 and C9 further suggest strong binding interactions. Therefore, compounds C8 and C9 are hits with potential after optimization for the development of anti-Parkinson’s disease agents.

**Materials and methods**

**Data set preparation**

Dual antagonists with binding constants (K<sub>i</sub>) for A<sub>1</sub>AR and A<sub>2A</sub>AR subtypes were investigated in the ChEMBL25 database [53]. A dataset consisting of 310 bioactive dual antagonists from approximately 100 series (K<sub>i</sub> < 40 nM) and 405 nonbioactive compounds in the same series (K<sub>i</sub> > 1000 nM) were used to train the DNN and CNN classification models. The dataset was divided into a training set, test set and validation set at a ratio of 7:2:1.

Canvas similarity and clustering from Schrödinger were used to calculate the Tanimoto coefficients (Tc) of similarity between every pair of structures among 310 dual antagonists (K<sub>i</sub> < 40 nM). Based on the calculated Tc values, similar structures were grouped together into the same cluster, yielding 14 clusters. Then, 14 representative structures of the diverse clusters were subsequently used to build dual antagonist pharmacophore models of the A<sub>1</sub>AR and A<sub>2A</sub>AR subtypes. To evaluate the performance of the pharmacophore models, an extra validation set comprising 42 dual antagonists (K<sub>i</sub> < 40 nM) of A<sub>1</sub>AR and A<sub>2A</sub>AR subtypes and 913 decoy compounds was applied. With respect to known dual antagonists, the decoys were selected from the ZINC database using DecoyFinder [60] based on the following criteria: (1) Tanimoto coefficient < 0.75, (2) number of hydrogen bond acceptors ± 2, (3) number of hydrogen bond donors ± 1, (4) MW ± 25, (5) logP ± 1, and (6) Tanimoto coefficient less than 0.9 with respect to the other decoys.

All compounds in the training set, test set, validation set and ChemDiv library were prepared using Schrodinger’s Ligprep (version 10.2, Schrödinger, LLC) with the default settings to convert 2D structures to 3D structures, add hydrogen atoms, and generate tautomers, stereoisomers and protonation states at pH 7.0 ± 2.0 using Epik (version 4.3, Schrödinger, LLC).

**DNN and CNN**

A deep neural network (DNN) (Fig 8A) is a neural network with a certain complexity. DNNs comprise multiple levels of nonlinear operations and have many hidden layers. Neurons transfer information or signals to other neurons according to the received input, forming a complex network, and learning through some feedback mechanism [61]. A convolutional neural network (CNN) (Fig 8B) is a feed-forward neural network consisting of one or more convolutional layers and a fully connected layer at the top (corresponding to a classic neural network).
CNNs also include associated weights and a pooling layer [62]. This structure enables the convolutional neural network to utilize the two-dimensional structure of the input data. Compared with other deep learning structures, convolutional neural networks can provide better results in image and speech recognition. Compared with other deep, feed-forward neural networks, convolutional neural networks need to consider fewer parameters, rendering these networks attractive deep learning structures.

Various statistical parameters were used to validate the performance of the DNN and CNN models. To evaluate the classification ability, parameters such as sensitivity \(SE\), specificity \(SP\), prediction accuracy of active molecules \(Q^+\), prediction accuracy of inactive molecules \(Q^-\), Matthews correlation coefficient \(MCC\) and the area under the receiver operating characteristic curve \(AUC\), were calculated using the following equations [63]:

\[
SE = \frac{TP}{TP + FN} \tag{1}
\]

\[
SP = \frac{TN}{TN + FP} \tag{2}
\]

\[
Q^+ = \frac{TP}{TP + FP} \tag{3}
\]

\[
Q^- = \frac{TN}{TN + FN} \tag{4}
\]

\[
MCC = \frac{TP \times TN - FN \times FP}{\sqrt{(TP + FN)(TP + FP)(TN + FN)(TN + FP)}} \tag{5}
\]

where \(TP\), \(FP\), \(TN\) and \(FN\) denote true positives, false positives, true negatives and false negatives, respectively.

In this study, we aimed to improve the performance of dual \(A_1/A_2A\) AR antagonist identification by deep learning. L2 regularization and “dropout” layers were used to prevent overfitting, and the rectified linear unit (ReLU) [64] was adopted as the activation function. The adaptive moment estimation (Adam) method [65] was used as an optimization algorithm for stochastic gradient descent in the process of training the deep learning models. In general, the performance of deep learning models is sensitive to the appropriate hyperparameters. To select the optimal hyperparameters for the deep learning models, a grid search approach [66] was used to optimize the hyperparameters based on the size of the training, including the learning rate, L2 regularization and number of hidden layers, and the size of the eigenvector in the hidden layers of the CNN model. In this stage, 209,585 and 171,233 compounds from the ChemDiv library (1,178,506 compounds) passed the filter that applied the DNN and CNN classification models, respectively. In total, 58,886 compounds that were simultaneously predicted by the DNN and CNN models were retained. The code and data sets used to train and test both the DNN and CNN models can be downloaded at [https://github.com/Houshujing/Adenosine](https://github.com/Houshujing/Adenosine).

**Pharmacophore modeling**

For the dual \(A_1/A_2A\) AR antagonist pharmacophore generation, 14 diverse structures \(K_i < 40\) nM selected from 310 dual antagonists were aligned in 3D space to generate common feature pharmacophores using the Phase module (version 5.4, Schrödinger, LLC). Each antagonist
structure was minimized using the OPLS-2005 force field [67] implemented in Macromodel (version 11.9, Schrödinger, LLC), and described by a list of pharmacophore sites to characterize the chemical features contributing to the compound-protein interactions between the antagonists and A1AR and A2AAR subtypes. The perceived pharmacophore hypotheses were identified once the pharmacophore features were common to 50% of the antagonists. The generated pharmacophore hypotheses were examined using an extra validation set consisting of 42 dual antagonists and 913 decoy compounds. In this stage, 5,629 of the 58,886 compounds that matched the pharmacophore model were retained.

Molecular docking
A Virtual Screening Workflow (version 7.8, Schrödinger, LLC) was used to perform the molecular docking calculations using the X-ray structures of A1AR cocrystallized with the antagonist PSB-36 (PDB ID 5N2S) and A2AAR cocrystallized with the antagonist ZM-241385 (PDB ID 5IU4). For each complex, the energy grid was generated at the centroid of the cocrystallized ligand. In addition, QikProp (version 5.5, Schrödinger, LLC) and Lipinski’s rule were applied to eliminate molecules with undesirable drug likeness properties. The 5,629 compounds that passed QikProp and Lipinski’s filters were docked and ranked sequentially using the Glide HTVS, SP and XP score functions based on the Glide score. The top 50% good scoring compounds through HTVS docking were filtered using SP. The top 25% good scoring compounds through SP docking were filtered using XP. Then, 43 of the top 25% good scoring compounds through XP against A1AR and A2AAR were further screened using visual inspection.

Functional assay
In this work, 19 tested compounds were purchased from J&K Scientific Ltd. (Shanghai, China). Functional assays were performed by Pharmaron (Beijing) as previously described [52] by evaluating AR-mediated cAMP production using CHO-A1 cells and HEK293-A2A cells stably expressing A1AR or A2AAR, respectively. The CHO-A1 cells and HEK293-A2A cells were cultured in growth medium (Ham’s F12K (A1AR)/DMEM (A2AAR) + 10% FBS + 1 μg/ml G418) at 37˚C and 5% CO2, collected by centrifugation and resuspended in Hank’s balanced salt solution (HBSS), 0.1% bovine serum albumin (BSA), 20 mM N-(2-hydroxyethyl)-piperazine-N0-ethanesulfonic acid (HEPES) and 100 nM 3-isobutyl-1-methylxanthine (IBMX). The test compounds were serially diluted in DMSO at 3-fold dilutions, resulting in 10 concentrations starting from 5.08 × 10⁻³ to 100 μM. To evaluate the antagonist activity, the test compounds were added to the cell plate, and their ability to counteract the agonist (5’-N-ethylcarboxamidoadenosine, NECA)-mediated decrease in cAMP accumulation was assessed. cAMP production was determined using an ALPHAScreen cAMP kit according to the manufacturer’s instructions.

Radioligand binding assays
The radioligand binding assays were also performed by Pharmaron (Beijing). In the A1AR and A2AAR assays, the test compounds were assessed in radioligand binding assays at human A1AR ([³H]DPCPX) and A2AAR ([³H]ZM241385). Displacement experiments of [³H]DPCPX (2.5 nM) against A1AR (4 μg/well) and ten different concentrations of test compounds were performed in 50 μL of assay buffer (50 mM Tris-HCl, 10 mM MgCl₂, 1 mM EDTA, 1 μg/ml adenosine deaminase, pH 7.4) for 50 min at 25˚C. The competition binding experiments of [³H]ZM241385 (0.5 nM) against A2AAR (4 μg/well) and ten different concentrations of the test compounds were performed in 500 μL of assay buffer (50 mM Tris-HCl, 10 mM MgCl₂, 1 mM EDTA, 1 μg/ml adenosine deaminase, pH 7.4) for 90 min at 27˚C.
Regarding the compounds that inhibited radioligand binding at A1AR and A2AAR by more than 50% at 100 μM, the IC50 values were determined from the sigmoidal concentration-response curves, which were generated using Xlfit (Version 5.3.1; IDBS, Guildford, UK). Depending on the IC50 values, the Ki values of the test compounds were calculated using the Cheng-Prusoff equation as follows: 

\[ K_i = IC_{50} / (1 + \frac{[C]}{K_d}) \]  

In this equation, \([C]\) and \(K_d\) are the concentration of the radioligand and the equilibrium dissociation constant of the radioligand, respectively. The \([C]/K_d\) of the radioligands \([3H]DPCPX\) and \([3H]ZM241385\) were 2.5 nM/2.1 nM and 0.5 nM/2.06 nM, respectively. S13 Fig shows the \(K_d\) determination curves of \([3H]DPCPX\) and \([3H]ZM241385\).

**Molecular dynamics simulations**

A1AR and A2AAR apo-proteins were extracted from the crystal structure of PSB36 or ZM241385 with thermally stable mutants A1AR or A2AAR (PDB ID: 5N2S and 5IU4) in the PDB database, respectively, and both apo-proteins and ligands were saved separately. The complex of PSB36 with thermostable mutant A1AR and the complex of ZM241385 with thermostable mutant A2AAR contain 9 and 10 mutation sites, respectively (5N2S: A54L, T88A, R107A, K122A, N154A, L202A, L235A, V239A, and S277A; 5IU4: M1P, A54L, T88A, R107A, K122A, N154A, L202A, L235A, V239A, and S277A). The mutant receptor residues were mutated back to the wild-type residues, the cocrystal T4 lysozyme was removed, and unnecessary small molecules were removed. The missing residues were added using the Prime module of Schrodinger. Hydrogen atoms were added through Schrodinger’s Protein Prepare module, and the protonation states of hydroxyl, Asn, Gln, and His in the structure were assigned by Schrodinger's ProtAssign module [69].

PSB36 and ZM241385 were docked, and the resulting docking poses had RMSD values less than 1.8 Å from the experimental structure (S14 Fig and S4 Table). Then, we docked C8, C9 and C10 using the same methods and chose the docking pose with the lowest binding free energy. The 6 ligand-receptor complexes C8-A1AR, C8-A2AAR, C9-A1AR, C9-A2AAR, C10-A1AR and C10-A2AAR were used to perform the MD simulations. The transmembrane regions of A1AR and A2AAR were calculated through the Orientations of Proteins in Membranes (OPM) database [70]. The amino acid numbers of the seven transmembrane fragments of A1AR are 8–31, 46–71, 79–103, 124–144, 175–201, 236–259 and 267–287. The amino acid numbers of the seven transmembrane fragments of A2AAR are 3–29, 40–68, 78–101, 118–141, 174–200, 234–258 and 267–288. Each complex was inserted into a 95 Å × 80 Å POPE phospholipid bilayer through visualized operations in VMD [71], solvated using the TIP3P water model [72] and neutralized using 0.15 M NaCl. Finally, each system contains approximately 71,500 atoms, with approximately 140 lipids and approximately 16,500 waters, and the simulation cell had dimensions of 95 Å × 80 Å × 110 Å.

The MD simulations were carried out in triplicate using the PMEMD algorithm of AMBER 18 software [73]. The AMBER ff14SB force field [74] was used for the A1AR and A2AAR systems. The standard protonation states of the protein residues were set at appropriate protonation states by the LEAP plugin in AMBER 18 as calculated using the H++ program [75]. The GAFF force field [76] and AMBER’s Antechamber were used to generate the topology and coordinate files of the compounds C8, C9 and C10. Lipid14 force field [77] was used for the POPE bilayer. First, each system was minimized by 10,000 steps. Second, a Langevin thermostat [78] was used to heat each system from 0 K to 310 K within 500 ps. Then, a 5-ns MD simulation in the NVT ensemble was performed while retaining the heavy atoms of the protein, ligand, and lipid head groups with a constraint of 50 kcal mol−1 Å−2. Third, an MD simulation
in the NPT ensemble was performed for 30 ns with a constraint for the protein and ligand. The restriction was gradually reduced from 50 (20 ns) to 10 (5 ns) and 2 kcal mol$^{-1}$ Å$^{-2}$ (5 ns). Finally, each system was simulated for 100 ns without constraints under constant pressure (NPT ensemble) using a Berendsen barostat [79]. The cutoff value for the nonbonded interactions was set to 12 Å. The SHAKE algorithm [80] was used to constrain the covalent bonds involving hydrogen atoms, and the PME algorithm [81] was applied to address remote electrostatic interactions. In the process of the dynamics simulation, the time steps were set to 2 fs, and the frames were saved for analysis every 5,000 steps. The CPPTRAJ tool in AMBER 18 and VMD software [71] were used to analyze the trajectories.

The binding free energy ($\Delta G_{\text{bind}}$) [82,83] between the ligand and the protein was calculated using the MM-GBSA method [84–86] of the Python script MMPBSA.py [87]. For the calculation, the dielectric constant of the solvent was set to 80, and the dielectric constant of the solute ($\mathcal{E}_\text{in}$) was set to 1 for the lipophilic binding area. The polar part of the free energy of desolvation ($\Delta G_{\text{GB}}$) was calculated using a modified GB model developed by Onufriev et al. [88]. The nonpolar part of the desolvation free energy ($\Delta G_{\text{SA}}$) was calculated based on the solvent accessible surface (SASA) prediction calculated by the LCPO algorithm [89].

**Supporting information**

**S1 Fig.** Matching graph of 19 compounds and a pharmacophore model (AAADR_1). (TIF)

**S2 Fig.** (A)—(I): Concentration-response curves of compounds against A$_1$AR in the cAMP assay. The data are presented as the mean ± SD of the inhibition percentage of cAMP production in duplicate assays. (TIF)

**S3 Fig.** (A)—(I): Concentration-response curves of compounds against A$_{2A}$AR in the cAMP assay. The data are presented as the mean ± SD of the inhibition percentage of cAMP production in duplicate assays. (TIF)

**S4 Fig.** (A)—(I): Concentration-response curves of compounds against A$_1$AR in the radioligand binding assay. The data are presented as the mean ± SD of the inhibition percentage of radioligand binding at A$_1$AR in duplicate assays. (TIF)

**S5 Fig.** (A)—(I): Concentration-response curves of compounds against A$_{2A}$AR in the radioligand binding assay. The data are presented as the mean ± SD of the inhibition percentage of radioligand binding at A$_{2A}$AR in duplicate assays. (TIF)

**S6 Fig.** Corresponding Tc values of MACCS and ECFP4 [55]. Distributions of the Tc values of MACCS and ECFP4 were determined by conducting 10 million comparisons between randomly selected ZINC compounds. Correspondence between the Tc values of MACCS and ECFP4 was established by relating these Tc values to others that were met or exceeded by the same percentage of comparisons (indicated as labeled points on the curve). (TIF)

**S7 Fig.** Stable bilayer after 100 ns of MD simulations. (A) C8-A$_1$AR complex embedded in the bilayer. (B) C9-A$_1$AR complex embedded in the bilayer. (C) C8-A$_{2A}$AR complex embedded in the bilayer. (D) C9-A$_{2A}$AR complex embedded in the bilayer. The proteins are shown
as blue (A₁AR) and green (A₂AAR) cartoons. The lipid molecules are represented as blue (A₁AR) and green (A₂AAR) lines. Sodium ions and chloride ions are represented as purple and green spheres. Water molecules are represented by red dots. (TIF)

**S8 Fig.** RMSDs of the protein in the C8-A₁AR complex (A), C9-A₁AR complex (B), C8-A₂AAR complex (C) and C9-A₂AAR complex (D) during the 100-ns MD simulations. (TIF)

**S9 Fig.** RMSDs of the ligand in the C8-A₁AR complex (A), C9-A₁AR complex (B), C8-A₂AAR complex (C) and C9-A₂AAR (D) during the 100-ns MD simulations. (TIF)

**S10 Fig.** N-N distance between 1,2,4-triazol and the side chain amino group of N254 in the C8-A₁AR complex (A) and C9-A₁AR complex (D). N-O distance between the 5-amino group and the side chain carbonyl of N254 in the C8-A₁AR complex (B) and C9-A₁AR complex (E). Distance between the centroids of 1,2,4-triazol and the side chain phenyl of F171 in the C8-A₁AR complex (C) and C9-A₁AR complex (F). (TIF)

**S11 Fig.** O-N distance between methanone and the side chain amino group of N253 in the C8-A₂AAR complex (A) and C9-A₂AAR complex (E). N-O distance between the 5-amino group and the side chain carbonyl of N253 in the C8-A₂AAR complex (B) and C9-A₂AAR complex (F). N-O distance between the 5-amino group and side chain of E169 in the C8-A₂AAR complex (C) and C9-A₂AAR complex (G). Distance between the centroids of 1,2,4-triazol and the side chain phenyl of F168 in the C8-A₂AAR complex (D) and C9-A₂AAR complex (H). (TIF)

**S12 Fig.** N-N distance between pyrazolo[1,5-a]pyrimidin and the side chain amino group of N254 (or N253) in the C10-A₁AR complex (A) and C10-A₂AAR complex (E). N-O distance between the N-propyl group and the side chain carbonyl of N254 in the C10-A₁AR complex (B). Distance between the centroids of pyrazole and the side chain phenyl of F171 (or F168) in the C10-A₁AR complex (C) and C10-A₂AAR complex (F). Distance between the centroids of pyrimidine and the side chain phenyl of F171 (or F168) in the C10-A₁AR complex (D) and C10-A₂AAR complex (G). (TIF)

**S13 Fig.** (A) Kd determination curves of [3H]DPCPX against A₁AR in the filtration binding assay. Nonspecific signal: Different ligand concentrations of 10 μM DPCPX; (B) Kd determination curves of [3H]ZM241385 against A₂AAR in the saturation binding assay. Nonspecific signal: Different ligand concentrations with 10 μM ZM241385. CPM = counts per minute, TB = total binding, NSB = nonspecific binding. (TIF)

**S14 Fig.** (A) Superposition of PSB36 in the orthosteric binding area of A₁AR at the experimental structure (shown as sticks in white color) and the resulting docking pose (in green). (B) Superposition of ZM241385 in the orthosteric binding area of A₂AAR at the experimental structure (shown as sticks in white color) and the resulting docking pose (in green). The protein is shown as a gray cartoon. The hydrogen bonds are represented by dashed lines. The side chains of F171, W247, H251, L253, N254, T257, H278, F168, N253, L267 and I274 in A₂AAR) are represented as lines. (TIF)
S1 Table. Training set for the dual A<sub>1</sub>/A<sub>2A</sub> AR antagonist pharmacophore models. (PDF)

S2 Table. Performance of various VS methods by screening the validation set with 433 dual A<sub>1</sub>/A<sub>2A</sub> AR antagonists and 11,605 decoys. (PDF)

S3 Table. Tc values of compounds C8 and C9 for Morgan, ECFP4 and MACCS. (PDF)

S4 Table. RMSD between the redocked and crystallized conformations of PSB36 and ZM241385 by Glide XP. (PDF)

Acknowledgments
This work was partially supported by computational resources by the Biodesign Center, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences.

Author Contributions
Conceptualization: Mukuo Wang, Jianping Lin.
Investigation: Mukuo Wang, Shujing Hou, Yu Wei, Dongmei Li.
Methodology: Mukuo Wang, Yu Wei, Jianping Lin.
Visualization: Shujing Hou.
Writing – original draft: Mukuo Wang, Yu Wei.
Writing – review & editing: Dongmei Li, Jianping Lin.

References
1. Kalia LV, Lang AE. Parkinson’s disease. The Lancet. 2015; 386(9996):896–912. https://doi.org/10.1016/s0140-6736(14)61393-3
2. Goetz CG. The history of Parkinson’s disease: early clinical descriptions and neurological therapies. Cold Spring Harb Perspect Med. 2011; 1(1):a008862. https://doi.org/10.1101/cshperspect.a008862 PMID: 22229124; PubMed Central PMCID: PMC3234454.
3. Shook BC, Rassnick S, Osborne MC, Davis S, Westover L, Boulet J, et al. In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson’s disease. J Med Chem. 2010; 53(22):8104–15. https://doi.org/10.1021/jm100971t PMID: 20973483.
4. Chaudhuri KR, Yates L, Martinez-Martin P. The non-motor symptom complex of Parkinson’s disease: a comprehensive assessment is essential. Curr Neurol Neurosci Rep. 2005; 5(4):275–83. https://doi.org/10.1007/s11910-005-0072-y PMID: 15987611
5. Lacombe E, Carcenac C, Boulet S, Feuerstein C, Bertrand A, Poupart A, et al. High-frequency stimulation of the subthalamic nucleus prolongs the increase in striatal dopamine induced by acute l-3,4-dihydroxyphenylalanine in dopaminergic denervated rats. Eur J Neurosci. 2007; 26(6):1670–80. Epub 2007/09/06. https://doi.org/10.1111/j.1460-9568.2007.05747.x PMID: 17822436.
6. Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Damier P, et al. Levodopa in the treatment of Parkinson’s disease: current controversies. Mov Disord. 2004; 19(9):997–1005. https://doi.org/10.1002/mds.20243 PMID: 15372588.
7. Mizuno Y. Definition and Classification of Parkinsonian Drugs. 2020. p. 1–30.
8. Laurencin C, Danaila T, Broussolle E, Thobois S. Initial treatment of Parkinson’s disease in 2016: The 2000 consensus conference revisited. Revue Neurologique. 2016; 172:512–23. https://doi.org/10.1016/j.neuro.2016.07.007 PMID: 27476416
9. Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, Piccini P, et al. Priorities in Parkinson's disease research. Nat Rev Drug Discov. 2011; 10(5):377–93. https://doi.org/10.1038/nrd3430 PMID: 21532567.

10. Lebon G, Warne T, Edwards PC, Bennett K, Langmead CJ, Leslie AG, et al. Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation. Nature. 2011; 474(7352):521–5. https://doi.org/10.1038/nature10136 PMID: 21593763; PubMed Central PMCID: PMC3146096.

11. Carpenter B, Nehmé R, Warne T, Leslie AGW, Tate CG. Structure of the adenosine A2A receptor bound to an engineered G protein. Nature. 2016; 536(7614):104–7. https://doi.org/10.1038/nature18966 http://www.nature.com/nature/journal/v536/n7614/abs/nature18966.html#supplementary-information. PMID: 27462812.

12. Garcia-Nafria J, Lee Y, Bai X, Carpenter B, Tate CG. Cryo-EM structure of the adenosine A2A receptor coupled to an engineered heterotrimeric G protein. Elife. 2018; 7. https://doi.org/10.7554/eLife.35946 PMID: 29726815; PubMed Central PMCID: PMC5962338.

13. Xu F, Wu H, Katritch V, Han GW, Jacobson KA, Gao ZG, et al. Structure of an agonist-bound human A2A adenosine receptor. Science. 2011; 332(6027):322–7. https://doi.org/10.1126/science.1202793 PMID: 21395908; PubMed Central PMCID: PMC3086811.

14. Jaakola VP, Griffith MT, Hanson MA, Cherezov V, Chien EY, Lane JR, et al. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science. 2008; 322(5905):1211–7. https://doi.org/10.1126/science.1164772 PMID: 18832607.

15. Liu W, Chun E, Thompson AA, Chubukov P, Xu F, Katritch V, et al. Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions. Science. 2012; 337(6091):232–6. https://doi.org/10.1126/science.1164772 PMID: 2219218 PMID: 21532567.

16. Sun B, Bachhwat P, Chu ML-H, Wood M, Ceska T, Sands ZA, et al. Crystal structure of the adenosine A2A receptor bound to an antagonist reveals a potential allosteric pocket. Proc Natl Acad Sci. 2017; 114(8):2066–71. https://doi.org/10.1073/pnas.1621423114 PMID: 28167788.

17. Dore AS, Robertson N, Errey JC, Ng I, Hollenstein K, Tehan B, et al. Structure of the adenosine A(2A) receptor in complex with ZM241385 and the xanthines XAC and caffeine. Structure. 2011; 19(9):1283–93. https://doi.org/10.1016/j.str.2011.06.014 PMID: 21885291; PubMed Central PMCID: PMC3732996.

18. Glukhova A, Thal DM, Nguyen AT, Vecchio EA, Jörg M, Scammells PJ, et al. Structure of the adenosine A1 receptor reveals the basis for subtype selectivity. Cell. 2017; 168(5):867–77. https://doi.org/10.1016/j.cell.2017.01.042 PMID: 28235198.

19. Cheng RKY, Segala E, Robertson N, Defflorian F, Dore AS, Errey JC, et al. Structures of Human A1 and A2A Adenosine Receptors with Xanthines Reveal Determinants of Selectivity. Structure. 2017; 25 (8):1275–85 e4. https://doi.org/10.1016/j.str.2017.06.012 PMID: 28712806.

20. Draper-Joyce CJ, Khoshoie M, Thal DM, Liang Y-L, Nguyen ATN, Furness SGB, et al. Structure of the adenosine-bound human adenosine A1 receptor–Gi complex. Nature. 2018; 558(7711):559–63. https://doi.org/10.1038/s41586-018-0236-6 PMID: 29925945.

21. Katritch V, Jaakola VP, Lane JR, Lin J, Ijzerman AP, Yeager M, et al. Structure-based discovery of novel chemotypes for adenosine A2A receptor antagonists. J Med Chem. 2010; 53(4):1799–809. https://doi.org/10.1021/jm901647p PMID: 20095623; PubMed Central PMCID: PMC2826142.

22. Carlsson J, Yoo L, Gao ZG, Irwin JJ, Shoichet BK, Jacobson KA. Structure-based discovery of A2A adenosine receptor ligands. J Med Chem. 2010; 53(9):3748–55. https://doi.org/10.1021/jm100240h PMID: 20405927; PubMed Central PMCID: PMC2865168.

23. Lagarias P, Vrontaki E, Lambrisidis G, Stamatis D, Convertino M, Orogo E, et al. Discovery of Novel Adenosine Receptor Antagonists through a Combined Structure- and Ligand-Based Approach Followed by Molecular Dynamics Investigation of Ligand Binding Mode. J Chem Inf Model. 2018; 58 (4):794–815. https://doi.org/10.1021/acs.jcim.7b00455 PMID: 29985875.

24. Fredholm BB, AP IU, Jacobson KA, Linden J, Muller CE. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors—an update. Pharmacol Rev. 2011; 63(1):1–34. https://doi.org/10.1124/pr.110.003285 PMID: 21303899; PubMed Central PMCID: PMC3061413.

25. Yacoubi ME, Ledent C, Parmentier M, Bertorelli R, Ongini E, Costentin J, et al. Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knock-out mice. Br J Pharmacol. 2001; 134(1):68–77. https://doi.org/10.1038/sj.bjp.0704240 PMID: 11522598.

26. Yamada K, Kobayashi M, Mori A, Jenner P, Kanda T. Antidepressant-like activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002), in the forced swim test and the tail suspension test in rodents. Pharmacol Biochem Behav. 2013;114–115:23–30. https://doi.org/10.1016/j.pbb.2013.10.022 PMID: 24201052.

27. Yamada K, Kobayashi M, Shiozaki S, Ohta T, Mori A, Jenner P, et al. Antidepressant activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) on learned helplessness in rats.
Psychopharmacology (Berl). 2014; 231(14):2839–49. https://doi.org/10.1007/s00213-014-3454-0 PMID: 24488405.

28. Chen J-F, Xu K, Petzer JP, Staal R, Xu Y-H, Beilstein M, et al. Neuroprotection by caffeine and A2A adenosine receptor inactivation in a model of Parkinson’s disease. J Neurosci. 2001; 21(10):RC143–RC. https://doi.org/10.1523/JNEUROSCI.21-10-j0011.2001 PMID: 11319241.

29. van Rensburg HJ, LeGobe L, Terre’Blanche G, Van der Walt M. 2–Benzyliene–1–Indanone Analogues as Dual Adenosine A1/A2a Receptor Antagonists for the Potential Treatment of Neurological Conditions. Drug Res. 2019; 69(07):382–91. https://doi.org/10.1055/a-0808-3993 PMID: 30616250.

30. Bortolotto JW, de Melo GM, de Paula Cognato G, Vianna MRM, Bonan CD. Modulation of adenosine signaling prevents scopolamine-induced cognitive impairment in zebrafish. Neurobiol Learn Mem. 2015; 118:113–9. https://doi.org/10.1016/j.nlm.2014.11.016 PMID: 25490060.

31. Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung K-H, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA. 2000; 283(20):2674–9. https://doi.org/10.1001/jama.283.20.2674 PMID: 10819950.

32. Shook BC, Rassnick S, Chakravarty D, Wallace N, Ault M, Crooke J, et al. Optimization of arylpyrimidines as potent adenosine A2A/A1 antagonists. Bioorg Med Chem Lett. 2010; 20(9):2868–71. https://doi.org/10.1016/j.bmcl.2010.03.024 PMID: 20338760.

33. Attack JR, Shook BC, Rassnick S, Jackson PF, Rhodes K, Drinkenburg WH, et al. JNJ-40255293, a novel adenosine A2A/A1 antagonist with efficacy in preclinical models of Parkinson’s disease. ACS Chem Neurosci. 2014; 5(10):1005–19. https://doi.org/10.1021/cc5001606 PMID: 25203719.

34. Shook BC, Jackson PF. Adenosine A2A Receptor Antagonists and Parkinson’s Disease. ACS Chem Neurosci. 2011; 2(10):555–67. https://doi.org/10.1021/cc2005357 PMID: 22860156; PubMed Central PMCID: PMC3369712.

35. Shook BC, Rassnick S, Wallace N, Crooke J, Ault M, Chakravarty D, et al. Design and characterization of optimized adenosine A2A/A1 receptor antagonists for the treatment of Parkinson’s disease. J Med Chem. 2012; 55(3):1402–17. https://doi.org/10.1021/jm201640m PMID: 22239465.

36. Mihara T, Mihara K, Yarimizu J, Mitani Y, Matsuda R, Yamamoto H, et al. Pharmacological characterization of a novel, potent adenosine A1 and A2 receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson’s disease and cognition. J Pharmacol Exp Ther. 2007; 323(2):708–19. https://doi.org/10.1124/jpet.107.121962 PMID: 17684118.

37. Mihara T, Iwashita A, Matsuoka N. A novel adenosine A(1) and A(2A) receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: comparison with existing anti-Parkinson’s disease drugs. Behav Brain Res. 2008; 194(2):152–61. https://doi.org/10.1016/j.bbr.2008.06.035 PMID: 18657577.

38. Robinson SJ, Petzer JP, Terre’Blanche G, Petzer A, van der Walt MM, Bergh JJ, et al. 2-Aminopyrimidines as dual adenosine A1/A2A antagonists. Eur J Med Chem. 2015; 104:177–88. https://doi.org/10.1016/j.ejmech.2015.09.035 PMID: 26462195.

39. Geldenhuys WJ, Hanif A, Yun J, Nayeem MA. Exploring Adenosine Receptor Ligands: Potential Role in the Treatment of Cardiovascular Diseases. Molecules. 2017; 22(6). https://doi.org/10.3390/molecules22060917 PMID: 28587166; PubMed Central PMCID: PMC5568125.

40. Antonioli L, Csoka B, Fornai M, Colucci R, Kokai E, Blandizzi C, et al. Adenosine and inflammation: what’s new on the horizon? Drug Discov Today. 2014; 19(8):1051–68. https://doi.org/10.1016/j.drudis.2014.02.010 PMID: 24607729.

41. Kristy A, Carpenter, David S, Cohen, Juliet T, Jarrell, et al. Deep learning and virtual drug screening. Future medicinal chemistry. 2018; 10(21):2557–67. https://doi.org/10.4155/fmc-2018-0314 PMID: 30288997.

42. Untherthner T, Mayr A, Klambauer G, Steijaert M, Hochreiter S, editors. Deep Learning as an Opportunity in Virtual Screening. Workshop on Deep Learning and Representation Learning (NIPS2014); 2014.

43. Lensenlink EB, ten Dijke N, Bongers B, Papadatos G, van Vlijmen HWT, Kowalczyk W, et al. Beyond the hype: deep neural networks outperform established methods using a ChEMBL bioactivity benchmark set. Journal of Cheminformatics. 2017; 9(1):45. https://doi.org/10.1186/s13321-017-0232-0 PMID: 29086168.

44. Bilisland AE, Pugliese A, Liu Y, Revie J, Burns S, McCormick C, et al. Identification of a Selective G1-Phase Benzimidazoleone Inhibitor by a Senescence-Targeted Virtual Screen Using Artificial Neural Networks. Neoplasia. 2015; 17(9):704–15. https://doi.org/10.1080/15286730.2015.08.009 PMID: 26476078.

45. Wallach I, Dzamba M, Heifets A. AtomNet: A Deep Convolutional Neural Network for Bioactivity Prediction in Structure-based Drug Discovery. Computer Science 2015.

46. Rifaioglu AS, Atalay V, Martin MJ, Celik-Atalay R, Science TJC. DEEPscreen: High Performance Drug-Target Interaction Prediction with Convolutional Neural Networks Using 2-D Structural Compound
47. Schaller D, Štrbar D, Noonan T, Deng L, Nguyen TN, Pach S, et al. Next generation 3D pharmacophore modeling. WIREs Computational Molecular Science. 2020; 10(4). https://doi.org/10.1002/wcms.1468
48. Lyu J, Wang S, Balius TE, Singh I, Levit A, Moroz YS, et al. Ultra-large library docking for discovering new chemotypes. Nature. 2019; 566(7743):224–9. https://doi.org/10.1038/s41586-019-0917-9 PMID: 30728502
49. Rogers D, Hahn M. Extended-connectivity fingerprints. Journal of Chemical Information Modeling. 2010; 50(5):742–54. https://doi.org/10.1021/ci100050t PMID: 20426451
50. Duvenaud D, Maclaurin D, Aguilera-Iparraguirre J, Gómez-Bombarelli R, Hirzel T, Aspuru-Guzik A, et al. Convolutional Networks on Graphs for Learning Molecular Fingerprints. Proceedings of the 28th International Conference on Neural Information Processing Systems. 2015;2:2224–32.
51. Truchon J-F OBayly CI. Evaluating Virtual Screening Methods: Good and Bad Metrics for the “Early Recognition” Problem. Journal of Chemical Information and Modeling. 2007; 47(2):488–508. https://doi.org/10.1021/ci600426e PMID: 17288412
52. Wei Y, Wang M, Li Y, Hong Z, Li D, Lin J. Identification of new potent A1 adenosine receptor antagonists using a multistage virtual screening approach. Eur J Med Chem. 2019; 187:411936. https://doi.org/10.1016/j.ejmech.2019.111936
53. Mendez D, Gaulton A, Bento AP, Chambers J, Veij MD, Félix E, et al. ChEMBL: towards directed deposition of bioassay data. Nucleic Acids Research. 2019; 47:D930–D40. https://doi.org/10.1093/nar/gky1075 PMID: 30398643
54. Berthold M, Cebron N, Dill F, Gabriel T, Kotter T, Aspuru-Guzik A, et al. KNIME—the Konstanz information miner. ACM SIGKDD Explorations Newsletter. 2009; 11:26–31. https://doi.org/10.1145/1656274.1656280
55. Maggiora G, Vogt M, Stumpfe D, Bajorath J. Molecular similarity in medicinal chemistry. J Med Chem. 2014; 57(8):3186–204. https://doi.org/10.1021/jm401411z PMID: 24151987.
56. Tratrat C, 1,2,4-Triazole A Privileged Scaffold For The Development Of Potent Antifungal Agents-A Brief Review. Current Topics in Medicinal Chemistry. 2020;July(4). https://doi.org/10.2174/187152491566615209100533 PMID: 25675400
57. Thakur A, Shukla P, Verma A, Pathak P. 1, 2, 4-Triazole Scaffolds: Recent Advances and Pharmacological Applications. International Journal of Current Research and Academic Review. 2016; 4:277–96. https://doi.org/10.20546/ijcrar.2016.402.031
58. Cereto-Massague A, Guasch L, Valls C, Muñoz M, Pujadas G, García-Vallejo S. DecoyFinder: An easy-to-use python GUI application for building target-specific decoy sets. Bioinformatics (Oxford, England). 2012; 28:1661–2. https://doi.org/10.1093/bioinformatics/bts249 PMID: 22539671
59. Kriegeskorte N. Deep Neural Networks: A New Framework for Modeling Biological Vision and Brain Information Processing. Annu Rev Vis Sci. 2015; 1:417–46. https://doi.org/10.1146/annurev-vision-082114-035447 PMID: 28532370.
60. Valueva MV, Nagornov NN, Lyakhov PA, Valuev GV, Chernyakov NI. Application of the residue number system to reduce hardware costs of the convolutional neural network implementation. Mathematics and Computers in Simulation. 2020; 177:232–43. https://doi.org/10.1016/j.matcom.2020.04.031
61. Jamal S, Scaria V. Cheminformatic models based on machine learning for pyruvate kinase inhibitors of Leishmania Mexicana. BMC Bioinformatics. 2013; 14(1):329. https://doi.org/10.1186/1471-2105-14-329 PMID: 24252103
62. Kutz CJ, Holshouser SL, Marrow EA, Woster PMJM. 3,5-Diamino-1,2,4-triazoles as a novel scaffold for potent, reversible LSD1 (KDM1A) inhibitors. Medchemcomm. 2014; 10:980–5. https://doi.org/10.1039/C4MD00283K PMID: 25588024
63. Thakur A, Shukla P, Verma A, Pathak P. 1, 2, 4-Triazole Scaffolds: Recent Advances and Pharmacological Applications. International Journal of Current Research and Academic Review. 2016; 4:277–96. https://doi.org/10.20546/ijcrar.2016.402.031
64. Cereto-Massague A, Guasch L, Valls C, Muñoz M, Pujadas G, García-Vallejo S. DecoyFinder: An easy-to-use python GUI application for building target-specific decoy sets. Bioinformatics (Oxford, England). 2012; 28:1661–2. https://doi.org/10.1093/bioinformatics/bts249 PMID: 22539671
65. Kriegeskorte N. Deep Neural Networks: A New Framework for Modeling Biological Vision and Brain Information Processing. Annu Rev Vis Sci. 2015; 1:417–46. https://doi.org/10.1146/annurev-vision-082114-035447 PMID: 28532370.
66. Valueva MV, Nagornov NN, Lyakhov PA, Valuev GV, Chernyakov NI. Application of the residue number system to reduce hardware costs of the convolutional neural network implementation. Mathematics and Computers in Simulation. 2020; 177:232–43. https://doi.org/10.1016/j.matcom.2020.04.031
67. Jamal S, Scaria V. Cheminformatic models based on machine learning for pyruvate kinase inhibitors of Leishmania Mexicana. BMC Bioinformatics. 2013; 14(1):329. https://doi.org/10.1186/1471-2105-14-329 PMID: 24252103
68. Nair V, Hinton G. Rectified Linear Units Improve Restricted Boltzmann Machines Vinod Nair2010. 807–14 p.
68. Yung-Chi C, Prusoff W. Relationship Between the Inhibition Constant (K_i) and the Concentration of Inhibitor Which Causes 50 Per Cent Inhibition (I_50) of an Enzymatic Reaction. Biochemical Pharmacology. 1973; 22:3099–108. https://doi.org/10.1016/0006-2952(73)90196-2 PMID: 4202581

69. Sastry GM, Adzhigirey M, Day T, Annabhimou R, Sherman W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput-Aided Mol Des. 2013; 27(3):221–34. https://doi.org/10.1007/s10822-013-9644-8 PMID: 23579614

70. Lomize MA, Pogozheva ID, Joo H, Mosberg HI, Lomize AL. OPM database and PPM web server: resources for positioning of proteins in membranes. Nucleic Acids Res. 2012; 40(D1):D370–D6. https://doi.org/10.1093/nar/gkr703 PMID: 21890895

71. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph. 1996; 14(1):33–8. https://doi.org/10.1016/0263-7855(96)00018-5 PMID: 8744570

72. Anandakrishnan R, Aguilar B, Onufriev AV. H++ 3.0: automating pK prediction and the preparation of biomolecular structures for atomistic molecular modeling and simulations. Nucleic Acids Res. 2012; 40(Web Server issue):W537–41. https://doi.org/10.1093/nar/gks375 PMID: 22570416; PubMed Central PMCID: PMC3394296.

73. Katritch V, Cherezov V, Stevens RC. Structure-function of the G protein-coupled receptor superfamily. Annu Rev Pharmacol Toxicol. 2013; 53(1):531–56. https://doi.org/10.1146/annurev-pharmtox-032112-135923 PMID: 23140243.

74. Maier JA, Martinez C, Kasavajhala K, Wickstrom L, Hauser KE, Simmerling C. ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB. J Chem Theory Comput. 2015; 11(8):3696–713. https://doi.org/10.1021/acs.jctc.5b00255 PMID: 26574453

75. Anandakrishnan R, Aguilar B, Onufriev AV. H++ 3.0: automating pK prediction and the preparation of biomolecular structures for atomistic molecular modeling and simulations. Nucleic Acids Res. 2012; 40(Web Server issue):W537–41. https://doi.org/10.1093/nar/gks375 PMID: 22570416; PubMed Central PMCID: PMC3394296.

76. Wang J, Wang W, Kollman PA, Case DA. Automatic atom type and bond type perception in molecular mechanical calculations. J Mol Graphics Modell. 2006; 25(2):247–60. https://doi.org/10.1016/j.jmgm.2005.12.005 PMID: 16458552

77. Dickson CJ, Madej BD, Skjevik AA, Betz RM, Teigen K, Gould IR, et al. Lipid14: the amber lipid force field. J Chem Theory Comput. 2014; 10(2):865–79. https://doi.org/10.1021/ct4010307 PMID: 24803855

78. Pastor RW, Brooks BR, Szabo A. An analysis of the accuracy of Langevin and molecular dynamics algorithms. Mol Phys. 1988; 65(6):3684–90.

79. Berendsen HJ, Postma Jv, van Gunsteren WF, DiNola A, Haak JR. Molecular dynamics with coupling to an external bath. J Chem Phys. 1984; 81(8):3684–90.

80. Ryczkaert J-P, Piccotti G, Berendsen HJ. Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys. 1977; 23(3):327–41.

81. Darden T, York D, Pedersen L. Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems. J Chem Phys. 1993; 98(12):10089–92.

82. Genheden S, Ryde U. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert opinion on drug discovery. 2015; 10(6):449–61. https://doi.org/10.1517/17460441.2015.1032936 PMID: 25835573

83. Miller BR III, McGee TD Jr, Swails JM, Homeyer N, Gohlke H, Roitberg AE. MMPBSA.py: an efficient program for end-state free energy calculations. J Chem Theory Comput. 2012; 8(9):3314–21. https://doi.org/10.1021/ct300418h PMID: 26605738

84. Tsui V, Case DA. Theory and applications of the generalized Born solvation model in macromolecular simulations. Biopolymers: Original Research on Biomolecules. 2000; 56(4):275–91. https://doi.org/10.1002/1097-0282(2000)56:4<275:AID-BIP10024>3.0.CO;2-E PMID: 11754341

85. Kollman PA, Massova I, Reyes C, Kuhn H, Roiitberg AE. MMPBSA.py: an efficient program for end-state free energy calculations. J Chem Theory Comput. 2012; 8(9):3314–21. https://doi.org/10.1021/ct300418h PMID: 26605738.

86. Miller BR III, McGee TD Jr, Swails JM, Homeyer N, Gohlke H, Roitberg AE. MMPBSA.py: an Efficient Program for End-State Free Energy Calculations. J Chem Theory Comput. 2012; 8(9):3314–21. https://doi.org/10.1021/ct300418h PMID: 26605738.

87. Miller BR III, McGee TD Jr, Swails JM, Homeyer N, Gohlke H, Roitberg AE. MMPBSA.py: an Efficient Program for End-State Free Energy Calculations. J Chem Theory Comput. 2012; 8(9):3314–21. https://doi.org/10.1021/ct300418h PMID: 26605738.

88. Onufriev A, Bashford D, Case DA. Modification of the generalized Born model suitable for macromolecules. The Journal of Physical Chemistry B. 2000; 104(15):3712–20.

89. Weiser J, Shenkin PS, Still WC. Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO). J Comput Chem. 1999; 20(2):217–30.